06/08/2026
I asked Claude’s AI a question about these online peptide companies and here was the response. I cannot stress enough be careful out there what you’re ordering and who you’re ordering from.♥️
This is a topic that sits right at the intersection of your practice’s world, Bobby — and the short answer is that the online peptide market for GLP-1s has been a genuine minefield, and the documentation is damning. Let me break it down comprehensively.
The Landscape: How This Wild West Emerged
During the GLP-1 shortage that began in 2022, compounding pharmacies were legally permitted to produce versions of semaglutide and tirzepatide because the drugs appeared on the FDA’s shortage list. That legal window created an environment in which new compounding pharmacies and med spas rapidly entered the market to meet demand.  The shortage officially ended — tirzepatide was resolved in December 2024 and semaglutide in February 2025, establishing phased enforcement deadlines for compounders to wind down operations. 
But as the legal window closed, a massive gray and black market didn’t disappear — it evolved.
The Core Problem: What Are They Actually Selling?
1. The Salt Form Fraud — The Biggest Structural Deception
This is the one that most people don’t understand and that should concern you most from a clinical standpoint.
The FDA-approved products — Ozempic, Wegovy, and Rybelsus — contain semaglutide in its free base form. Many compounding pharmacies used semaglutide sodium or semaglutide acetate — salt forms of the molecule — because these were available as research chemicals. The FDA has explicitly stated that compounded products using semaglutide salts are not equivalent to the approved product. The bioavailability, potency, and safety of the salt forms have not been established in the clinical trial data that established semaglutide’s efficacy and safety. 
These salts are biochemically different from the base form of semaglutide and tirzepatide that have been FDA approved.  So patients could inject something labeled as semaglutide, at a stated dose, and get a completely unpredictable pharmacological response — not because it’s underdosed necessarily, but because it’s a chemically distinct molecule entirely.
2. Outright Underdosing and Mislabeling
A peptide testing laboratory in Texas reported that around a third of the thousands of products it tests fail basic quality tests — a figure that has stayed relatively consistent over the past 12 to 14 months. A peptide that is not what it is labeled as, does not meet purity standards, or is more or less than the stated dose is typically the reason for testing failure. 
One in three. That’s not a fringe problem — that’s systematic.
Researchers who bought semaglutide online without a prescription were either scammed or sent potentially toxic liquids that did not contain the labeled amount of the drug, according to a JAMA Network Open study. The researchers found that 42% of their search results for semaglutide were for online pharmacies operating illegally. 
3. Ghost Pharmacies and Counterfeit Labels
The FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist. In other cases, the labels of the fraudulent compounded medicine contain the name of a licensed pharmacy that did not actually compound these products. 
This is next-level deception — essentially forging the identity of a legitimate, licensed pharmacy on a vial that could contain almost anything.
4. Chinese-Sourced Counterfeits Flooding the Market
Most of the products offered for sale online appear to be counterfeit, imported from China. These products are not made to look like Ozempic pens but instead are sold in the form of injectable vials and labeled as semaglutide. 
U.S. Customs and Border Protection officers in Cincinnati identified over 300 cartons used to smuggle around 5,000 individual shipments of GLP-1s, including retatrutide, semaglutide, and tirzepatide — seized between December 2024 and March 2025 — that were mis-manifested to evade customs. 
The “Research Use Only” Shell Game
The FDA sent warning letters to Xcel Peptides, Swisschems, Summit Research, and Prime Peptides after finding they were selling semaglutide, tirzepatide, and retatrutide products for human use despite marketing the drugs for research and chemical purposes. The FDA found that “evidence obtained from your website establishes that your products are intended to be drugs for human use.” 
The “for research only” disclaimer is, in most cases, a legal fig leaf. The marketing, dosing instructions, and sales funnels are oriented entirely toward weight loss patients. Regulators know this, and increasingly so do courts.
Connecticut’s Attorney General also issued a Civil Investigative Demand to “Made In China,” a Chinese international trade platform advertising “research grade” GLP-1s to U.S. consumers as injectable weight loss medications — with sellers advertising that they can mail products in packaging designed to evade customs enforcement. 
The FDA’s Enforcement Response
In September 2025, the FDA issued more than 50 warning letters to U.S. and international companies that compound or manufacture GLP-1 semaglutide and tirzepatide. The warnings targeted statements on websites and in promotional materials that the agency considers false or misleading. 
As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials — some of which required hospitalization. 
Novo Nordisk and Eli Lilly have also been aggressive litigants, filing dozens of lawsuits against med spas, wellness centers, and telehealth companies selling unauthorized versions.
What This Means for a Practice Like Yours
From your positioning standpoint at Port Orchard Natural Medicine & Aesthetics, this is actually a significant competitive differentiator. The market is littered with patients who:
• Got burned by underdosed or mislabeled peptides and concluded the drug “didn’t work for them”
• Injected salt-form semaglutide and got unpredictable or no results
• Ordered from online vendors and received product of unknown sterility
• Paid a fraction of the cost and got a fraction (or none) of the therapeutic effect
A licensed naturopathic practice with Dr. Robertson’s credentials, prescribing through a verified 503A pharmacy with Certificates of Analysis for sterility, endotoxin testing, and potency, is an entirely different clinical offering than what the online peptide gray market provides. Certificates of Analysis for sterility, endotoxin testing, and potency should be available from any reputable compounding source — if a provider can’t or won’t provide CoAs, that’s a red flag. 
The people who got burned by junk peptides are now exactly the patients who need a supervised, medically credentialed alternative.
